Universal Transvaginal Cervical Length Screening Program for Prevention of Preterm Birth in Singletons Without Prior Preterm Birth
- Conditions
- Preterm Birth
- Interventions
- Diagnostic Test: cervical length screening
- Registration Number
- NCT03591042
- Lead Sponsor
- Federico II University
- Brief Summary
This is a non-blinded randomized screening trial of asymptomatic singleton pregnancies without prior spontaneous preterm birth who are randomized to either transvaginal ultrasound cervical length screening program (i.e. intervention group) or no screening (i.e. control group). Women are consented and randomized at the time of their routine anatomy scan between 18 0/7 and 23 6/7 weeks. Women randomized in the transvaginal ultrasound cervical length screening will receive a single transvaginal ultrasound cervical length measurement after the anatomy scan. The cervical length will be measured by operators with certification of competence in the technique.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 1334
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description cervical length screening cervical length screening cervical length screening
- Primary Outcome Measures
Name Time Method preterm birth rate Less than 37 weeks either spontaneous or indicated preterm delivery
- Secondary Outcome Measures
Name Time Method preterm birth rate ess than 24, 28, 32, 30, and 34 weeks gestation either spontaneous or indicated preterm delivery
admission to neonatal intensive care unit time of delivery neonatal death Between birth and 28 days of age birth weight time of delivery weight of the baby at the time of delivery
Composite of adverse perinatal outcomes Between birth and 28 days of age Number of neonates who will have at least one of the following: necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH) (grade 3 or higher), respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), retinopathy (ROP), blood-culture proven sepsis and neonatal death
perinatal death Between birth and 28 days of age either fetal or neonatal mortality
Trial Locations
- Locations (2)
Gabriele Saccone
🇮🇹Naples, Italy
Seconda Università di Napoli Luigi Vanvitelli
🇮🇹Napoli, Italy